Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.

Expert review of clinical pharmacology

Volumn 6, Issue 5, 2013, Pages 483-502

  Morimoto, Bruce H ^a   Fox, Anthony W ^b   Stewart, Alistair J ^b   Gold, Michael ^b  

^a Allon Therapeutics Inc   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAVUNETIDE; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE;

ANIMAL; APOPTOSIS; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFECTS; HUMAN; MICROTUBULE; NEURODEGENERATIVE DISEASES; PATHOLOGY; TOXICITY TESTING; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROTUBULES; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; TOXICITY TESTS; TREATMENT OUTCOME;

EID: 84899594297     PISSN: None     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.827403     Document Type: Review

References (0)